| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not yet assigned | Inotuzumab Ozogamicin | Besponsa | 0.9 mg | Immunotherapy | Drug Antibody Conjugate | CD22 | No | 2017 | In Use | |||
| C9069 | Belantamab mafodotin-blmf | Blenrep | 0.5mg | Immunotherapy | Drug Antibody Conjugate | BCMA | No | 2020 | Jan 1, 2021 | No Longer Used | ||
| J1323 | Elranatamab-bcmm | Elranatamab-bcmm | 1mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2023 | Apr 17, 2024 | In Use | ||
| Q2057 | Afamitresgene autoleucel | Tecelra | per therapeutic dose | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | No | 2024 | Mar 26, 2025 | In Use | ||
| C9303 | Zolbetuximab-clzb | Vyloy | 1mg | Immunotherapy | Monoclonal Antibody | CLDN18.2 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| J9177 | Enfortumab vedotin-ejfv | Padcev | 0.25mg | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | No | 2019 | Jul 1, 2020 | In Use | ||
| Q2041 | Axicabtagene Ciloleucel | Yescarta | Up to 200 million | Immunotherapy | CAR-T | CD19 | No | 2017 | Jan 1, 2019 | In Use | ||
| NA | Thalidomide | Thalomid | 50 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
| C9131 | Ado-Trastuzumab Emtansine | Kadcyla | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2 | No | 2013 | Jul 1, 2013 | Dec 31, 2013 | No Longer Used | |
| C9082 | Dostarlimab-gxly | Jemperli | 100mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
| Q9979 | Alemtuzumab | Lemtrada | 1 mg | Immunotherapy | Monoclonal Antibody | CD52 | No | 2001 | Oct 1, 2015 | Dec 31, 2015 | No Longer Used | |
| Not yet assigned | Tisagenlecleucel | Kymriah | consult labeling | Immunotherapy | CAR-T | CD19 | No | 2017 | In Use | |||
| NA | Thalidomide | Thalomid | 100 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
| J9380 | Teclistamab cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Jul 11, 2023 | In Use | ||
| J9030 | Bacillus calmette-guerin | BCG Vaccine, Tice BCG | 1mg | Immunotherapy | Biological Response Modifier | Live Vaccine | No | 1990 | Jul 1, 2019 | In Use | ||
| J9274 | Tebentafusp-tebn | Kimmtrak | 1mcg | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | No | 2022 | Sep 27, 2022 | In Use | ||
| J9022 | Atezolizumab | Tecentriq | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2016 | Jan 1, 2018 | In Use | ||
| Q2024 | Bevacizumab | Avastin | 0.25 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Oct 1, 2009 | Dec 31, 2009 | No Longer Used | |
| C9306 | Telisotuzumab vedotin-tllv | Emrelis | 1mg | Immunotherapy | Drug Antibody Conjugate | c-MET | No | 2025 | 2026 | Sep 8, 2025 | Jan 12, 2026 | In Use |
| J8499 | Immunotherapy - non specific | Prescription drug, oral, non chemotherapeutic, nos | NA | Immunotherapy | Yes | Jan 1, 1995 | In Use | |||||
| C9165 | Elranatamab-bcmm | Elrexfio | 1mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2023 | Dec 7, 2023 | Apr 17, 2024 | No Longer Used | |
| J9144 | Daratumumab, hyaluronidase-fihj | Darzalex Faspro | 10mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2020 | Jan 1, 2021 | In Use | ||
| Q2043 | Sipuleucel-T | Provenge | 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf | Immunotherapy | Immunomodulator | Prostatic Acid Phosphatase | No | 2010 | Jul 1, 2011 | In Use | ||
| C9491 | Avelumab | Bavencio | 10 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2017 | Oct 1, 2017 | In Use | ||
| J9356 | Trastuzumab and Hyaluronidase-oysk | Herceptin hylecta | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2019 | Jul 1, 2019 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home